comparemela.com

Latest Breaking News On - Swiss research institutes for high altitude climate - Page 1 : comparemela.com

Seed Health and the Swiss Institute of Allergy and Asthma Research Launch Novel Immunology Platform to Develop the Next Generation of Microbiome and Barrier-Safe Personal Care Products

Nature article presents impact and importance of epithelial barrier damage on a range of common diseases

Nature article presents impact and importance of epithelial barrier damage on a range of common diseases News provided by Share this article STOCKHOLM, April 15, 2021 /PRNewswire/   SciBase Holding AB ( SciBase ) [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today the publication of a  groundbreaking article presenting the epithelial barrier hypothesis in Nature Reviews Immunology. The article was written by Professor Cezmi Akdis at the Swiss institute of Allergy and Asthma Research (SIAF). Prof. Akdis is the key research collaborator in SciBase s product development for skin barrier assessment. The article presents the background for the steep increase in allergic diseases over the last decades, and how this increase is connected to industrialization and modern lifestyle.

Nature article presents impact and importance of epithelial barrier damage on a range of common diseases

Nature article presents impact and importance of epithelial barrier damage on a range of common diseases
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

New clinical study shows Nevisense potential for assessment of Skin Barrier and Atopic Dermatitis

New clinical study shows Nevisense potential for assessment of Skin Barrier and Atopic Dermatitis News provided by Share this article STOCKHOLM, April 12, 2021 /PRNewswire/ SciBase Holding AB ( SciBase ) [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today the publication of a new clinical study supporting SciBase s strategy to develop multiple clinical applications for the Nevisense and Nevisense Go platforms. The study is from the Swiss institute of Allergy and Asthma Research (SIAF) and has been published in the European Journal of Allergy and Clinical Immunology (Allergy). In the study Nevisense was used to assess the skin barrier of patients with atopic dermatitis (AD) and could accurately detect signs of atopic dermatitis even on unaffected skin. The Nevisense measurement also correlated with relevant biomarkers for atopic dermatitis.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.